Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $265 | $55 | $33 | $201 |
| Short-Term Investments | $1,090 | $504 | $302 | $133 |
| Receivables | $8 | $9 | $2 | $2 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $13 | $6 | $8 | $9 |
| Total Curr. Assets | $1,375 | $574 | $345 | $345 |
| Property Plant & Equip (Net) | $56 | $57 | $5 | $5 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $1 | $2 | $2 | $1 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $2 | $0 | $1 |
| Total NC Assets | $59 | $61 | $7 | $6 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $1,435 | $635 | $352 | $351 |
| Liabilities | – | – | – | – |
| Payables | $6 | $7 | $7 | $3 |
| Short-Term Debt | $7 | $4 | $1 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $2 | $2 | $2 | $0 |
| Other Curr. Liab. | $45 | $31 | $18 | $13 |
| Total Curr. Liab. | $60 | $44 | $28 | $16 |
| LT Debt | $45 | $48 | $2 | $3 |
| Deferred Rev, NC | $5 | $5 | $6 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $1 | $0 | $0 | $0 |
| Total NC Liab. | $50 | $52 | $8 | $3 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $52 | $48 | $2 | $3 |
| Total Liabilities | $110 | $96 | $36 | $19 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $2,276 | $1,192 | $759 | $608 |
| Retained Earnings | -$952 | -$654 | -$439 | -$275 |
| AOCI | $1 | $1 | -$4 | -$0 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $1,325 | $539 | $316 | $332 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $1,435 | $635 | $352 | $351 |
| Net Debt | -$213 | -$3 | -$30 | -$198 |